Biomarkers Task Force 2014 - present

The Biomarkers Task Force initiative was made possible by the:

Steering Committee

Chair

Lisa H. Butterfield, PhD
University of Pittsburgh Cancer Institute

Co-Chairs

Mary L. Disis, MD
University of Washington

Bernard A. Fox, PhD
Earle A. Chiles Research Institute

Samir N. Khleif, MD
Georgia Health Sciences

Francesco Marincola, MD
Sidra Medical and Research Center

FDA Liaison

Raj K. Puri, MD, PhD
U.S. Food and Drug Administration

Working Group 1 - Immunologic Monitoring, Assay Standardization & Validation

Co-Chairs

Guiseppe V. Masucci, MD, PhD
Karolinska University Hospital, Solna

Magdalena Thurin, PhD
National Cancer Institute

Members

John Alvarez, MD, PhD
Janssen R&D

Alessandra Cesano, MD, PhD
 NanoString Inc.

Kevin K. Dobbin, PhD
University of Georgia

Rachael Hawtin, PhD
Nodality

Sylvia Janetzki, MD
Zellnet Consulting, Inc.

Ilan Kirsch, MD
Adaptive Technologies

Raj K. Puri, MD, PhD
FDA, CBER

Paul Robbins, PhD
MedImmune

Senthamil R. Selvan, PhD
Omni Array Biotechnology

Howard Z. Streicher, MD
National Cancer Institute - Cancer Therapy Evaluation Program

Zhe Zhang, PhD
BioHealth Innovation

Working Group 2 - New Developments in Biomarker Assays & New Technologies

Chair

Jianda Yuan, MD
Merck

Members

Raphael Clynes, MD, PhD
Bristol-Myers Squibb

Periklis Foukas, MD, PhD
University Hospital of Lausanne

Bernard A. Fox, PhD
Earle A. Chiles Research Institute

Alexandre Harari, PhD
University Hospital of Lausanne

Priti Hegde, PhD
Genentech

Thomas O. Kleen, PhD
Epiontis GmbH

Pia Kvistborg, PhD
Netherlands Cancer Institute

Christina Maccalli, PhD
Department of Translational Medicine, Sidra Medical and Research Department

Holden T. Maecker, PhD
Stanford University Medical Center

Harlan Robins, PhD
Adaptive Biotechnologies Corporation

Wenru Song, MD, PhD
AstraZeneca

Edward C. Stack, PhD
PerkinElmer

Ena Wang, MD
Sidra Medical and Research Center

Theresa L. Whiteside, PhD
University of Pittsburgh Cancer Institute

Yingdong Zhao, PhD
National Cancer Institute

Heinz Zwierzina, MD
Innsbruck Medical University

Working Group 3 - Assessment of Immune Regulation & Modulation Systematically (High Throughput Approaches)

Chair

David F. Stroncek, MD
National Institutes of Health

Members

Michael Cannarile, PhD
Roche Innovation Center Zurich

Madhav Dhodapkar, MD
Yale University

Tim Greten, MD
National Institutes of Health

David Kaufman, MD, PhD
Merck Research Laboratories

Peter P. Lee, MD
City of Hope

Francesco Marincola, MD
Sidra Medical and Research Center

Sergio Rutella, MD, PhD
Sidra Medical and Research Center

Barbara Seliger, MD, PhD
Martin Luther University Halle-Wittenberg

Janet Siebert, MS
CytoAnalytics

Giorgio Trinchieri, MD
National Cancer Institute

Working Group 4 - Prediction of Clinical Outcome Based on Baseline Measures

Chair

Sacha Gnjatic, PhD
Ican School of Medicine at Mount Sinai

Members

Vincenzo Bronte, MD
University of Verona

Laura Rosa Brunet, DSc
Immodulon

Marcus Butler, MD
Princess Margaret Cancer Centre

Mary L. Disis, MD
University of Washington

Jerome Galon, MD
INSERM - Cordeliers Research Center

Leif G. Hakansson, MD, PhD
Cancer Drug Development Forum

Brent A. Hanks, MD, PhD
Duke University Medical Center

Vaios Karanikas, PhD
Roche Innovation Center Zurich

Samir N. Khleif, MD
Georgia Cancer Center

John M. Kirkwood, MD
University of Pittsburgh

Lance Miller, PhD
Wake Forest School of Medicine

Laura Rosa Brunet, DSc
Immodulon Therapeutics Ltd

Dolores J. Schendel, PhD
Medigene Immunotherapies GmbH

Isabelle Tanneau, MSc
ImmuneID

Jon M. Wigginton, MD
Macrogenics, Inc.